share_log

Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8

Benzinga ·  Sep 18, 2023 09:41

Citigroup analyst Yigal Nochomovitz maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $2.1 to $1.8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment